In this chapter:
- Key information
- 13.1. Bacteriology
- 13.2. Clinical features
- 13.3. Epidemiology
- 13.4. Vaccines
- 13.5. Recommended immunisation schedule
- 13.6. Contraindications and precautions
- 13.7. Potential responses and AEFIs
- 13.8. Public health measures
- 13.9. Variations from the vaccine data sheets
Download: Meningococcal disease (pdf, 366 KB)
Mode of transmission
By respiratory droplets or direct contact with nasopharyngeal secretions from a carrier or case.
2–10 days, commonly 3–4 days.
Period of communicability
Commonly 3–4 days without treatment, range 2–10 days. Certain antibiotic therapy eradicates N. meningitidis from mucosal surfaces within 24 hours, and the case is no longer considered infectious.
Other available vaccines
Dose, presentation, route
0.5 mL per dose.
Funded vaccine indications
MenACWY (Menactra/MenQuadfi), MenC (NeisVac-C) and MenB (Bexsero) for:
MenACWY (Menactra/MenQuadfi) for:
Laboratory workers handling bacterial cultures
Health care professionals in very close contact with cases.
MenACWY: 80–85%; effectiveness wanes to 50–60% within 2–5 years after vaccination.
MenC: effectiveness of 83–100%; antibody wanes within 2–3 years.
MenB: 75% reduction in group B cases in infants over a 3-year period in the UK and cross-protection against group W observed; 71% reduction in group B disease in adolescents.
Potential responses to vaccines
MenC and MenACWY: localised pain, irritability, headache and fatigue, mild fever.
MenB: increased risk of fever and fever-related events in children <2 years (prophylaxic antipyretic advised). Older age groups: localised pain, nausea, myalgia, malaise, mild fever and headache.
No specific contraindications or precautions, except prior anaphylaxis to vaccine components.
Public health measures
All cases must be notified if clinically suspected.
Parenteral antibiotics should be administered as soon as possible before admission to hospital or in hospital if delays of longer than 30 minutes are likely.
For chemoprophylaxis of contacts see section 13.8.2.
Meningococcal disease is caused by Neisseria meningitidis, a gram-negative bacterium, causing sepsis, meningitis and some less common clinical syndromes. Groups B and W are currently the most important types in New Zealand. Increasingly, group W and Y organisms are the cause of bacteraemia and pneumonia in the elderly. Predominant groups differ between countries; group A is an important epidemic strain, particularly in Africa and the Middle East. Meningococci are spread from person to person by respiratory droplets or direct contact with nasopharyngeal secretions from a carrier or case.
13.2. Clinical features
Table 13.1 below describes the symptoms and signs of meningococcal disease – individuals may present with some or all of these. Meningococcal septicaemia is more common than meningitis, and presentation varies from a mild non-specific illness to rapid progression with fatal outcome. Symptoms and signs in infants are frequently non-specific. The classical rapidly progressing petechial or purpuric rash may not be present or may initially appear maculopapular. Atypical initial presentations, including gastrointestinal symptoms, septic arthritis and epiglottitis, are more frequently reported with meningococcal W disease, and may contribute to delayed diagnosis and increased case-fatality.[1, 2] Pneumonia is more frequently reported with group Y.
Meningococcal disease covers a spectrum, from persistent fever with or without rash and arthritis to rapidly progressive purpuric rash and shock. Meningitis can occur with and without signs of sepsis. In fulminant cases, coma and death can occur within a few hours despite appropriate treatment.
Because of the potential for rapid progression, antibiotics should be administered (Table 13.2) as soon as possible before hospital admission. Antibiotics given prior to transfer should be clearly noted on information accompanying the patient to hospital.
- Patients allergic to penicillin who do not have a documented history of anaphylaxis to penicillin can be given ceftriaxone.
- Patients with a documented history of anaphylaxis to penicillin and who are suspected of suffering from meningococcal disease should be sent immediately to hospital without pre‑admission antibiotics.
13.3.1. Global burden of disease
Incidence and serotypes
The prevalence of meningococcal groups varies geographically. The highest burden of disease occurs in sub-Saharan Africa, where despite a dramatic fall in Group A disease following introduction of a Group A conjugate vaccine, in this ‘meningitis belt’ epidemics continue with around 30,000 cases reported annually, now including Group W.
The incidence in Canada, the US and Europe varies substantially from 0.2 to 3 per 100,000 persons per year. Group B has become the predominant capsular group in Europe, Americas and Australia, with incidence typically highest in children aged under 2 years. Group C disease has almost disappeared in countries with universal immunisation programmes, but outbreaks have been observed in men who have sex with men in the US and Europe.
Since 2009 there has been an emerging global incidence of Group W disease, initially in the United Kingdom and South America. Australia has experienced a rapid increase in Group W cases since 2013 with New Zealand also seeing a rapid increase in cases since 2017. Like group C clonal complex ST11 strains, group W ST11 strains have enhanced virulence. Higher rates of carriage of these ST11 strains has been noted within age groups where invasive group W disease is more prevalent (infants and the elderly).
Some parts of the world, particularly Scandinavia, have reported an increase in group Y disease. In other regions, there is evidence of colonisation, but disease caused by group Y is rare. Patients with group Y strain disease are more likely to develop pneumonia and to be elderly.[3, 4]
This emergence of group W and Y strains has led to meningococcal C vaccines being replaced by quadrivalent (group A, C, W, Y) meningococcal conjugate vaccines (MenACWY).
The highest incidence of meningococcal disease occurs in children aged under 5 years (especially under 2 years) with a secondary peak in older adolescents (15–19 years).The age distribution for groups W and Y is more likely to include older people that for B and C. A pooled overall case-fatality rate of 8.3 percent (range 4.1–20 percent) is reported internationally, varying by group and age.
Most infection occurs in healthy people, but those with certain rare immune deﬁciencies (of terminal components of complement (C5–9) or properdin) or asplenia are at much higher risk, particularly of recurrent meningococcal disease. Individuals with infection caused by groups other than A, B, C, W, Y and untypeable strains or who experience recurrent disease should be investigated.
Close contacts of primary cases of meningococcal infection are at increased risk of developing infection, such as the case’s household, early childhood education services, semi-closed communities, schools, correctional facilities and military recruit camps. Students living in hostel accommodation may also be at higher risk.[8, 9, 10] In health care settings, only those with close exposure to oropharyngeal secretions of patients with meningococcal disease (as may occur during intubation or resuscitation) and microbiology laboratory workers are considered to be at increased risk.
It is not possible to calculate the incubation period for meningococcal disease for sporadic cases. Secondary cases (ie, in contacts of known cases of meningococcal disease) usually occur within four days, but it can be up to 10 days. The infectivity of patients with meningococcal disease is markedly reduced after 24 hours of antibiotic therapy, although treatment with cefotaxime, ceftriaxone, rifampicin or ciproﬂoxacin is necessary to reliably eradicate nasopharyngeal (see section 13.8.2).
In high-income countries in the absence of immunisation, nasopharyngeal carriage of N. meningitidis occurs in approximately 10 percent of the overall population, rising from 2 percent in children aged under 4 years to a peak of 24.5 percent to 32 percent among 15–24-year-olds, then declining with increasing age.[3, 11] In adolescents and young adults, the overall and capsular group carriage vary between regions and age groups. The relationship between risk factors for disease and those associated with carriage is incompletely understood. Carriage prevalence does not predict the disease incidence nor the occurrence or severity of outbreaks, as most of the carried strains are non-encapsulated and do not cause disease. Smoking, passive smoking, household crowding and upper respiratory tract infections increase carriage.
13.3.2. New Zealand epidemiology
Incidence and mortality
In 2021 the notification rate for meningococcal disease was 0.9 cases per 100,000 population, with a total of 44 cases notified (40 laboratory confirmed; ESR, 28 April 2022). Cases remained significantly lower than the peak annual incidence rate of 16.7 per 100,000 for all ages and 200 per 100,000 in children under 12 months as experienced in 2001 during the meningococcal epidemic from 1991 to 2007. The epidemic was largely due to a single Group B subtype (B:P1.7-2,4). The annual number of notified cases of meningococcal disease in New Zealand since 1970 is shown in Figure 13.1.
For further details and reports of meningococcal disease in New Zealand refer to the ESR surveillance reports.
Figure 13.1: Notified cases of meningococcal disease, 1970–2021
Meningococcal disease incidence is highest in Māori (2.6 per 100,000, 22 cases in 2021) compared with the total population. Household crowding is an important risk factor for meningococcal disease, independent of ethnicity. In 2021, the highest age-specific disease rates were among those aged under 1 year (27.8 per 100,000, 17 cases) decreasing in ages 1–4 years (2.0 per 100,000, 5 cases). Three deaths occurred in 2021, giving a case fatality rate of 6.8 percent (ESR, 28 April 2022).
From 1 January to 31 October 2022, there were 60 cases of meningococcal disease (57 confirmed cases), which was an increase from the same period in 2020 and 2021 but lower than for the previous years in 2017, 2018 and 2019. Of these cases 45 percent were children aged under 5 years of Māori and Pacific ethnicity.
Strain type was determined for 36 of the 40 laboratory-confirmed cases in 2021. Group B strains were the most prevalent, causing 81 percent of the typed cases (Figure 13.2). The group B strain (B:P1.7b,4) responsible for the epidemic caused 22 percent of all meningococcal disease in 2021 (8 of the 36 typed cases). Cases of meningococcal disease caused by group C strains decreased since 2014 (Figure 13.2), while group W increased from five cases in 2016 to 36 in 2019. Cases in groups C, W and Y decreased in 2021, likely in part, due to the public health measures implemented to control the COVID-19 pandemic. Only group B increased from 2020.
In 2022 to 31 October, out of 48 cases with group identified, 39 (81 percent) were group B, six (13 percent) were group Y and three (6 percent) group W. There were 14 different PorA types identified within the group B cases. The most common were B:P1.7-12, 14 (14 cases) and B:P1.7-2,4 (ten cases).
Figure 13.2: Meningococcal disease notifications by group, 2014–2021
13.4.1. Available vaccines
Internationally, meningococcal vaccination programmes were revolutionised by the development of conjugate vaccines, which allow vaccination in younger children and induced herd immunity when used in population-wide programmes due to reduced nasopharyngeal carriage (see section 1.4.3).
The monovalent (C) and quadrivalent (ACWY) conjugate vaccines are conjugated to a protein, either CRM197 (diphtheria toxin-derived), diphtheria toxoid or tetanus toxoid. Previously used, polysaccharide-only vaccines provided three to five years’ protection in adults, but they are generally regarded as inferior to conjugate vaccines and are no longer available or registered in New Zealand. Those travelling to Africa, the Middle East and other areas with wide serogroup prevalence, including group A, require MenACWY vaccine for broad protection. In 2018, a multicomponent meningococcal group B recombinant vaccine (MenB, formerly abbreviated 4CMenB) was registered in New Zealand to protect against group B disease.
With the current New Zealand epidemiology, neither MenACWY nor MenB give protection across all prevailing meningococcal groups and both types of vaccine are recommended. The meningococcal vaccines registered and available are summarised in Table 13.3 below.
No meningococcal vaccines are on the routine Schedule, currently. See section 13.5 for funded vaccine for special groups.
Three meningococcal vaccines are funded for certain special groups (see section 13.5).
- Recombinant meningococcal B vaccine, MenB (Bexsero, GSK) contains four components from the group B meningococcus: three recombinant N. meningitidis group B surface proteins associated with bacterial adhesion and survival (Neisseria heparin binding antigen fusion protein, adhesin A protein, and factor H binding protein) plus detoxified outer membrane vesicles containing antigen as used in the MenNZB epidemic vaccine. Other components include aluminium hydroxide, sodium chloride, histidine and sucrose.
- Meningococcal group C conjugate vaccine MenC (NeisVac-C, Pfizer NZ Ltd) contains 10 µg of polysaccharide derived from the group C capsule, conjugated to 10–20 µg of tetanus toxoid. Other components include aluminium hydroxide and sodium chloride.
- Quadrivalent meningococcal conjugate vaccine MenACWY-D (Menactra, Sanofi) contains 4 µg of each polysaccharide derived from the capsules of group A, C, W and Y N. meningitidis strains, each conjugated to diphtheria toxoid. Other components include sodium chloride and sodium phosphate.
MenQuadfi (sanofi-aventis) is a tetanus toxoid conjugated quadrivalent meningococcal vaccine (MenACWY-T) approved for use in New Zealand for individuals aged from 12 months. It is anticipated to replace Menactra as the funded vaccine in early 2023. This vaccine is a fully liquid formulation that does not require reconstitution. Each 0.5 mL dose contains 10 µg of capsular polysaccharide conjugated to 55 µg tetanus toxoid for each of the N. meningitidis group A, C, W and Y strains. Also contains sodium chloride, sodium acetate and water for injection. There is no preservative or adjuvant.
A second MenACWY-T vaccine (Nimenrix, Pfizer NZ) is available for use in New Zealand for individuals from age 6 weeks. This MenACWY vaccine contains 5 µg of each polysaccharide derived from the capsules of group A, C, W and Y N. meningitidis strains, conjugated to 44 µg of tetanus toxoid carrier protein. Other components and excipients include sodium chloride, trometamol and sucrose.
A two-component meningococcal group B recombinant vaccine (MenB-fHbp; Trumenba, Pfizer Ltd) is licensed from 10 years of age, including in the US, Europe and Australia. It is not available in New Zealand.
Historic MeNZB vaccine
A strain-specific group B meningococcal vaccine (MeNZB, Chiron/Novartis) containing outer membrane vesicles derived from the epidemic strain B:4:P1.7b,4 (NZ 98/254) was developed for epidemic control in New Zealand and used between 2004 and 2008. The programme ceased in 2008 because of a decline in incidence of epidemic strain group B disease (see previous editions of the Handbook).
Since the immune response to MenNZB was short-lived, previous recipients who wish to be protected against meningococcal B disease will need to be fully immunised with MenB.
13.4.2. Efficacy and effectiveness
Meningococcal conjugate vaccines
Quadrivalent meningococcal conjugate vaccines
Clinical trial data use immunogenicity and bactericidal antibody titres as a proxy for efficacy. Effectiveness of conjugate meningococcal vaccination against laboratory-confirmed disease is difficult to assess due to the low incidence of cases, even during localised epidemics, such that data is limited around the effectiveness of the MenACWY vaccines. With the emergence of group W and Y strains, more countries have implemented mass campaigns and routine immunisation programmes to control outbreaks with MenACWY vaccines and can assess impact through disease incidence and carriage studies.
The overall effectiveness of a single dose of diphtheria conjugate quadrivalent meningococcal vaccine (MenACWY-D, Menactra) given at age 11–12 years was estimated to be 69 percent up to eight years post-vaccination (from 79 percent in year one to 61 percent up to eight years post-vaccination). These findings cannot be extrapolated across all MenACWY vaccines due to differences in immunogenicity.
Following a mass vaccination campaign in children aged 9 months to 4 years in Chile with MenACWY (MenACWY-D or MenACWY-CRM, depending on age), there was a 92.3 percent reduction in group W disease and the case-fatality rate declined from 23 percent in 2012 to 0 percent in 2016 in children aged 1–4 years. However, there was no impact in infants aged under 12 months or adults aged 80 years or older.
The MenACWY-D vaccine was poorly immunogenic in infants aged under 6 months, and it is currently registered in New Zealand for individuals aged 9 months to 55 years.
Several phase II and III clinical trials have assessed the immunogenicity of the MenACWY vaccine, MenQuadfi. These studies have included healthy vaccine-naive toddlers aged from 12 months; vaccine-naïve older children and adolescents; booster doses in toddlers, children and adolescents following prior MenACWY or MenC vaccination; given concurrently with routine vaccines (DTaP-IPV-HepB/Hib, MMR, VV, PCV13, Tdap and HPV); and in adults aged over 56 years. In all studies, robust antibody responses were observed in all groups, immunogenicity was non-inferior to comparator vaccines and booster responses were observed. One clinical trial observed lower antibody responses to FHA, PRN and FIM2/3 pertussis antigens but not pertussis toxin, when MenACWY was given concurrently with Tdap and HPV in adolescents compared with without MenACWY. The clinical relevance is unknown and has been observed with other MenACWY vaccines. No interference was documented with other vaccines. There is no published data to date on effectiveness or use in immunocompromised individuals.
The other MenACWY-T vaccine (Nimenrix) is registered in New Zealand for individuals from aged 6 weeks. Clinical trials showed that the vaccine elicited bactericidal antibodies against all four groups from age 2 months with acceptable reactogenicity and safety profile.
There is no published data on effectiveness in older adults for these vaccines.
Meningococcal group C conjugate vaccines
Meningococcal C conjugate vaccines were used successfully in national immunisation and mass vaccination programmes from 1999 in the UK, resulting in almost complete elimination of group C disease. A targeted immunisation campaign during an epidemic in Salvador, Brazil demonstrated MenC vaccination to be 98 percent effective against group C disease in young children. A booster dose in the second year of life was indicated in the UK for sustained protection. The greatest impact from meningococcal immunisation campaigns was obtained through herd immunity and a reduction in transmission was observed across all age groups, including in unvaccinated adults, where catch-up programmes in adolescents were implemented.[24 25]
With the emergence of group W and group Y meningococci, MenC has largely been replaced by MenACWY vaccines on national programmes for infants and adolescents.
Meningococcal group B recombinant vaccine
Three years after initiation of the introduction of MenB to the national immunisation schedule in the UK, a 75 percent reduction in group B disease was reported in the vaccine-eligible age groups compared with a historical cohort. With 88 percent coverage but a low number of cases (25), adjusted vaccine effectiveness for all group B strains was 59.1 percent (95% CI: -31.1–87.2) following two primary doses and one booster dose, with an estimated 277 cases prevented. This research is ongoing.
Following MenB vaccination of adolescents aged 15-16 years in South Australian schools, there was an overall reduction of 71 percent (95% CI 15-90; p=0.02) in group B meningococcal disease cases aged 16-19 years: five cases in 2017–2018 (predicted 9.9 [95% predicted interval 3.9-17.5]) and one case in 2018–2019 (predicted 10.9 [4.4–19.1]).
As was observed during college outbreaks in the US,[28, 29] in South Australia where MenB is administered in a school-based programme at age 15–18 years, MenB had no effect on disease-causing meningococcal carriage suggesting that vaccination of adolescents is unlikely to generate herd immunity. A MenB vaccination campaign used during an isolated outbreak in a region of Québec, Canada outbreak demonstrated direct protection of 79 percent against outbreak strain group B disease and an overall impact of 86 percent in target groups with no herd effects.
Cross-protection against meningococcal group W has been observed following vaccination of infants with MenB in the UK. Among age-cohorts that were fully and partially eligible to receive MenB, respectively, it was estimated that there were 69 percent (adjusted incidence rate ratio 0.31; 95% CI 0.2-0.67) and 52 percent (0.48; 0.28-0.81) fewer cases of group W disease than predicted in 2018/2019; this included direct and indirect protection over four years. An estimated 98 cases (95% CI 34-201) of group W disease were directly prevented in children aged under 5 years. The researchers state that MenACWY conjugate vaccines would still be required for direct and indirect protection against those groups, since the degree of cross-protection is dependent on the expression of vaccine antigens on the meningococcal surface.
There is limited data on its use in patients with chronic medical conditions and those immunocompromised by medication or disease, such as HIV infection or hereditary immune system defects. In a phase 3 clinical trial, children aged 2–17 years showed good but reduced immunogenicity in those with immunocompromise. Immunogenicity in children with asplenia and splenic dysfunction was similar to healthy children but reduced in children with complement deficiencies.
The safety and efficacy of MenB in adults above 50 years of age have not been established.
13.4.3. Transport, storage and handling
Transport according to the National Standards for Vaccine Storage and Transportation for Immunisation Providers 2017 (2nd edition).
Store at +2°C to +8°C. MenACWY vaccines and MenB should be protected from light. Do not freeze.
MenACWY-T (Nimenrix) must be reconstituted with the supplied diluent and used as soon as possible. The other meningococcal vaccines are fully liquid formulations and do not require reconstitution.
13.4.4. Dosage and administration
Quadrivalent meningococcal conjugate vaccines (MenACWY)
Each MenACWY dose is 0.5 mL, administered by intramuscular injection (see section 2.2.3).
MenACWY-D (Menactra) is registered in New Zealand for individuals aged 9 months to 55 years. See Table 13.5 for schedules for certain special groups.
- For children aged 9–23 months, two doses are given at least three months apart.
- For individuals aged 2–55 years, one dose is given.
- Booster doses may be indicated in some high-risk individuals.
MenACWY-D can be concurrently administered with other vaccines in separate syringes and at separate sites,[35, 36, 37, 38] except for PCV13. MenACWY-D should preferably be administered at least four weeks after PCV13. This is because, when administered concurrently, there is possible blunting of the immune response to some of the pneumococcal serotypes.[39, 40] (see section 13.5.2 for recommendations in regard to high-risk children age under 12 months and section 4.3.3).
MenACWY-T (MenQuadfi) is approved for use in New Zealand given as a single dose to individuals aged 12 months and over. It is anticipated to be available in early 2023 to replace Menactra.
A single booster dose may be given to adolescent and adults who have been primed with another MenACWY vaccine at least 4 years previously. There is currently no data available to indicate the need for or timing of a booster dose.
MenACWY can be concurrently administered with other vaccines in separate syringes and at separate sites.
MenACWY-T (Nimenrix) is registered (not funded) in New Zealand for individuals from age 6 weeks.
- For infants aged under 12 months, two doses are given eight weeks apart, plus a booster from age 12 months at least six months after second dose.
- Healthy infants aged 6 months to under 12 months, who are not immunocompromised, can be given one dose instead of two primary doses, plus a booster from age 12 months, at least eight weeks later.
- For adults and children from age 12 months, one dose is given.
- Booster doses may be indicated in some individuals.
MenACWY-T can be concurrently administered with other vaccines in separate syringes and at separate sites.
Meningococcal group C conjugate vaccine (MenC)
Each MenC (NeisVac-C) dose is 0.5 mL, administered by intramuscular injection (see section 2.2.3). See Table 13.5 for schedules for at-risk individuals.
For infants aged under 12 months, two doses are given at least eight weeks apart, with the first dose given not earlier than age 6 weeks. One dose of MenACWY is recommended in the second year of life from age 12 months.
MenC can be administered concurrently with other scheduled vaccines, in separate syringes and at separate sites.
In view of the New Zealand epidemiology, a quadrivalent (MenACWY) vaccine would be preferable, to obtain broader meningococcal protection.
Meningococcal group B recombinant vaccine (MenB)
Each MenB (Bexsero) dose is 0.5 ml, administered by intramuscular injection (see section 2.2.3).
- For infants aged 6 weeks to 11 months, two doses are given with a minimum of eight weeks between doses, with a booster given at least six months after the second dose, from age 12 months.
- For toddlers aged 12–23 months (at time of first dose) a primary course of two doses is given at least eight weeks apart. A booster dose is recommended from 12 to 23 months after dose two.
- For children aged from 2 years (at time of first dose) and adults, two doses are given at least eight weeks apart. (Note: the safety and efficacy in individuals aged over 50 years have not been established, but no safety concerns are expected.)
Generally, the need for booster doses from the age 2 years or older at the time of their first dose has not been established. A booster dose can be considered for individuals at continued risk of exposure to meningococcal disease. Booster doses are funded five-yearly for some high-risk individuals (see Table 13.5).
MenB can be administered concurrently with other scheduled vaccines, in separate syringes and at separate sites.
Note: MenB elicits a robust immune response, sometimes with high fevers in some infants. Routine use of paracetamol with every dose of MenB in children aged under 2 years, whether given alone or with other vaccines, is recommended to reduce the risk of high fever and injection-site pain. Some infants will still develop a fever and/or injection-site pain even though they have received paracetamol doses.
Prophylaxic paracetamol is recommended to be given 30 minutes prior to and six-hourly for up to 48 hours following vaccination for children aged under 2 years. For children and infants aged from 2 months, ibuprofen may be given as an alternative to paracetamol.
13.5. Recommended immunisation schedule
13.5.1. Individuals at increased risk
Meningococcal vaccines are not on the Schedule, currently, but are funded in special circumstances, as described in the shaded section of Table 13.4; Table 13.5 shows the recommended dosing schedules.
See sections 4.3, 4.4 and 4.5 for more information about vaccination of special groups, including recommended immunisation schedules for high-risk individuals with certain medical conditions.
The meningococcal vaccines are recommended (but not funded) for other individuals at risk, as described in non-shaded rows in Table 13.4.
There are areas of the world where the risk of meningococcal disease is increased. Nevertheless, the risk to travellers to the developing world has been estimated as being less than one in a million per month. Recurrent epidemics of meningococcal disease occur in the sub-Saharan ‘meningitis belt’, from Senegal in the west to Ethiopia in the east, usually during the dry season (December to June). Epidemics are occasionally identiﬁed in other parts of the world, including in Europe and the Americas. Generally, countries outside of Africa experience smaller outbreaks, but case-fatality rates can be high.
The preferred vaccines (MenACWY and/or MenB) for travel would be based on the epidemiology of the country. For website sources for information about meningococcal vaccines for travellers, see the WHO website. Quadrivalent meningococcal vaccine is a requirement for pilgrims to the Hajj.
Before moving into communal living situations
MenACWY-D is recommended and funded from age 13–25 years inclusively for individuals who will be living in communal accommodation within the next three months, or who are in their first year of living in communal accommodation (specifically, boarding school hostels, tertiary education halls of residence, military barracks or prisons) as they are likely to be at higher risk of acquiring meningococcal infection.
Recommended and funded
MenC or MenACWY (according to age) and MenB are recommended and funded for:
MenACWY is recommended and funded for:
Recommended but not funded
MenACWY and MenB are recommended, but not funded, for:
MenACWY-T (Nimenrix) is recommended but not funded for high-risk infants age under 9 months in place of MenC.
MenB is recommended but not funded for all the above high-risk groups.
MenACWY and MenB are recommended but not funded for all infants, young children, adolescents and young adults.
- Pneumococcal, Hib, influenza and varicella vaccines are also recommended for individuals pre- or post-splenectomy or with functional asplenia. See section 4.3.4.
- See section 4.3.4 for more information.
- The period of immunosuppression due to steroid or other immunosuppressive therapy must be longer than 28 days.
- For close contacts and individuals who have had previous meningococcal disease, given as per the routine dosage schedule (see section 13.4.4).
- Regardless of time elapsed since disease. Vaccination can commence at any time from when the person is no longer acutely unwell.
Age at diagnosis
Recommended vaccine schedule
Infants aged 6 weeks to under 12 months
Children aged 12 months to under 18 years
(Menactra or MenQuadfi)
Adults aged 18 years and older
(Menactra or MenQuadfi)
Give 2 doses 8 weeks apart, then 1 dose every 5 years.a,b
|MenB (Bexsero)||Give 2 doses 8 weeks apart, then booster 5 yearly.c|
Individuals aged between 13 and 25 years, in certain communal living situationsd
(Menactra or MenQuadfi)
1 dose, no booster required
- Give MenACWY-D (Menactra) at least 4 weeks before or after PCV13[38, 39] (see below).
- MenACWY-D is registered for individuals aged 9 months to 55 years, but there are not expected to be any safety concerns when administered to adults older than 55 years. Likewise, MenB is licenced to age 50 years but no safety concerns are expected when given to adults aged over 50 years.
- MenB booster funded for individuals pre- and post-splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre- or post-solid organ transplant.
- Funded for individuals aged 13–25 years inclusively who either: are entering within three months or who are in their first year of living in boarding school hostels, tertiary education halls of residence, military barracks or prisons.
There is a possibility of blunting of some PCV serotype antibody responses when MenACWY-D (Menactra) is given concurrently with the PCV13 series because both vaccines contain diphtheria-derived proteins as conjugates. The clinical significance of this blunting, observed in a clinical trial with PCV7, is unknown and the affected serotypes (4, 6B, 18C) are currently rare in New Zealand. The benefits of achieving broad meningococcal protection as early as possible in immunocompromised infants outweigh the theoretical risk of modest reduction of some pneumococcal antibody levels, so MenACWY-D is recommended at 9 months rather than waiting until the PCV13 series is completed (see Table 4.5, Table 4.6 and Table 13.5). Note: two doses given at least three months apart are recommended as a primary series; ideally, each dose should be given at least four weeks before or after PCV13 to reduce this risk of interference, but PCV13 and MenACWY-D can be given together or at any interval for pragmatic reasons or if an accelerated schedule is required.
13.5.2. Recommendations for children and adolescents
In the absence of a universal programme, non-high-risk children and adolescents may be offered meningococcal vaccines, but these are not funded. Table 13.6 suggests the most appropriate ages for this, reflecting the known ages of increased risk. The predominant meningococcal strains in New Zealand in childhood are B, W and C. With the current New Zealand epidemiology, neither MenACWY nor MenB give protection across all prevailing meningococcal groups and both types of vaccine are recommended. For those who are likely to travel, the broadest protection is preferable because of the differing serotype patterns between countries.
- Refer to section 13.4.4 for the intervals between doses.
- Prophylaxis paracetamol (or ibuprofen as age-appropriate) is recommended for this age group, see section 13.7.3.
- Infants aged from 6 months to ≤12 months who are not immunocompromised, can instead be given one dose plus booster from age 12 months at least two months later.
- MenACWY-D should be administered at least four weeks after PCV13 (if used).
- In particular, for individuals aged 13–25 years not eligible for funded vaccine, particularly living in crowded private homes, other hostels or student accommodation, or planning overseas travel.
13.5.3. Pregnancy and breastfeeding
There are no reports of any adverse effects among pregnant women who have been vaccinated during pregnancy. Meningococcal vaccines may be given in pregnancy and to those who are lactating, if indicated.[39, 42]
Meningococcal conjugate vaccines, MenC (age 12 months), MenACWY (Menactra from age 9 months or MenQuadfi from 12 months, as available) and MenB are funded for vaccination or re-vaccination of eligible individuals, as follows. See also section 4.3.
Meningococcal conjugate vaccines
For MenC (age under 12 months) and MenACWY (Menactra from age 9 months or MenQuadfi from age 12 months, as available), up to three doses plus booster doses (as appropriate) are funded for individuals:
- pre- or post-splenectomy
- pre- or post-solid organ transplantation
- with functional asplenia
- with complement deficiency (acquired or inherited)
- who are HIV-positive.
Two doses are funded for individuals:
- post-haematopoietic stem cell transplantation
- prior to planned and following immunosuppression for longer than 28 days.
Recombinant meningococcal B vaccine, MenB
- Age under 12 months – up to three doses plus booster after age 12 months and every five years (as appropriate)
- Age from 12 – 23 months – up to two doses plus booster given 12 to 23 months after second dose and every five years (as appropriate)
- Age from 2 years – up to two doses plus a booster every five years (as appropriate)
Funded for individuals:
- pre- or post-splenectomy
- pre- or post-solid organ transplantation
- with functional or anatomic asplenia
- with complement deficiency (acquired or inherited)
- who are HIV-positive
- post-haematopoietic stem cell transplantation
- prior to planned and following immunosuppression for longer than 28 days.
13.6. Contraindications and precautions
See also section 2.1.3 for pre-vaccination screening guidelines and section 2.1.4 for general contraindications for all vaccines.
There are no speciﬁc contraindications for meningococcal vaccines, except for anaphylaxis to a previous dose or any component of the vaccine.
13.7. Potential responses and AEFIs
13.7.1. Quadrivalent meningococcal conjugate vaccine
Potential adverse reactions after meningococcal conjugate vaccines include localised injection-site pain, irritability, headache, malaise and fatigue.[20, 43] The safety profile of all the MenACWY vaccines are very similar.[20, 40, 41] In infants, unusual crying, irritability, drowsiness and vomiting have been reported in clinical trials.[44, 45] Fever is reported by 2–5 percent of adolescents and less than 10 percent of infants who receive MenACWY. Concurrent administration with routine vaccines did not increase solicited systemic responses in young children (when given with PCV13) but was slightly increased in adolescents (with Tdap and HPV) during clinical trials of MenQuadfi.[40, 44, 45]
There is no evidence of an association between meningococcal conjugate vaccines and GBS. An early report in the US of a suspected temporal association between MenACWY-D (Menactra) and GBS was followed by a large retrospective cohort study in the US that found no evidence of an increased risk of GBS following administration of MenACWY-D.[39, 46] If indicated, meningococcal conjugate vaccines may be administered to individuals with a history of GBS.
13.7.2. Meningococcal group C conjugate vaccine
A Cochrane Review assessed the safety of MenC against group C disease. MenC vaccines were shown to have an excellent safety profile in infants. The events more frequently reported in infants were fever (1–5 percent), irritability (38–67 percent), crying more than expected (1–13 percent), redness at the site of vaccination (6–97 percent), tenderness at the site of vaccination (11–13 percent) and swelling at the site of vaccination (6–42 percent). Anaphylaxis was reported at a rate of one per 500,000 doses distributed.
13.7.3. Meningococcal B recombinant vaccine
There is an increased risk of fever and medically attended fever-related events, such as febrile seizures, associated with MenB in some children age under 2 years.[4, 49, 50, 51, 52] These events peaked at six hours post-vaccination and generally subsided by day 3. Prophylaxic paracetamol is recommended 30 minutes prior and six-hourly for up to 48 hours following vaccination for children aged under 2 years. Ibuprofen may be given as an alternative to paracetamol. Some infants will still develop a fever and/or injection-site pain even though they have received paracetamol doses.
In clinical trials, some infants and young children also experienced injection-site tenderness and irritability. Adolescents and adults may experience localised pain, nausea, myalgia, malaise, mild fever and headache.
13.8. Public health measures
Invasive meningococcal disease must be notified on suspicion to the local medical officer of health.
The overall rate of secondary cases in untreated adults is around 1 per 300. Adults and children in close contact with primary cases of invasive meningococcal infection are recommended to receive antibiotic prophylaxis, preferably within 24 hours of the initial diagnosis, but prophylaxis is recommended up to 14 days after diagnosis of illness.
Blood or cerebrospinal fluid culture is the main diagnostic method, but blood PCR may be useful if antibiotics are given without prior access to blood culture. It is recommended that in primary care 3–5 mL of blood should be taken in an ethylenediaminetetraacetic acid (EDTA) anticoagulant tube (usually with a purple top) prior to administration of antibiotics unless blood culture is available. This should accompany the patient to hospital.
A contact is anyone who has had unprotected contact with upper respiratory tract or respiratory droplets from the case during the seven days before onset of illness to 24 hours after onset of effective treatment. Contacts at particular risk include:
- those sleeping at least one night in the same household, dormitory, military barrack or student hostel bunkroom (not residents of nursing or residential homes who sleep in separate rooms) as the case, or who have been in a seat adjacent to the case in a plane, bus or train for more than eight hours
- health care workers who have had intensive unprotected contact (not wearing a mask) with a case during intubation, resuscitation or close examination of the oropharynx
- exchange of upper respiratory tract secretions, including intimate kissing
- other contacts as determined by the medical officer of health on a case-by-case basis, such as children and staff attending an early childhood service.
Prophylaxis is not routinely recommended for health care personnel unless there has been intimate contact with oral secretions (eg, performing mouth-to-mouth resuscitation or suctioning of the case before antibiotic therapy has started).
13.8.2. Chemoprophylaxis for contacts
The recommended antibiotics are rifampicin, ceftriaxone or ciprofloxacin, preferably given within 24 hours of initial diagnosis, but prophylaxis is recommended up to 14 days after diagnosis of illness.
The recommended dose of rifampicin is 10 mg/kg (maximum dose 600 mg) every 12 hours for two days. For infants aged under 4 weeks, the recommended dose is 5 mg/kg every 12 hours for two days.
Rifampicin should be avoided for pregnant or lactating women.
A single dose of intramuscular ceftriaxone (125 mg for children aged under 12 years and 250 mg for older children and adults) has been found to have an efﬁcacy equal to that of rifampicin in eradicating the meningococcal group A carrier state. Ceftriaxone is the drug of choice in a pregnant woman because rifampicin is not recommended later in pregnancy. Ceftriaxone may be reconstituted with lignocaine (according to the manufacturer’s instructions) to reduce the pain of injection. A New Zealand study demonstrated that ceftriaxone and rifampicin were equivalent in terms of eliminating nasopharyngeal carriage of N. meningitidis group B.
Do not use in infants under aged under 4 weeks.
Ciproﬂoxacin given as a single oral dose of 500 mg or 750 mg is also effective at eradicating carriage. This is the preferred prophylaxis for women on the oral contraceptive pill and for prophylaxis of large groups.
Ciproﬂoxacin is not generally recommended for pregnant and lactating women or for children aged under 18 years. Consult the manufacturer’s data sheet for appropriate use and dosage of ciprofloxacin in children.
Use of meningococcal vaccines for close contacts
Close contacts of cases of any group (including group A, B, C, W or Y) meningococcal disease may be offered both MenB and MenACWY (or MenC if aged under 9 months) meningococcal vaccines (see section 13.5).
See below for the use of the vaccines for the control of outbreaks, as initiated by the local public health service.
13.8.3. Outbreak control
When there is an outbreak of meningococcal disease of a specific vaccine group, an immunisation programme may be recommended and funded for a deﬁned population. The local medical officer of health will determine the necessary action in discussion with the Ministry of Health.
For more details on control measures, refer to the ‘Neisseria meningitidis invasive disease’ chapter of the Communicable Disease Control Manual .
13.9. Variations from the vaccine data sheets
The MenACWY-D data sheet states that the vaccine is indicated for use in individuals aged 9 months to 55 years. The Ministry of Health recommends that this vaccine can be used in adults aged over 55 years.
The data sheet states that MenACWY-D should be given as a single dose for individuals aged 2 years and older. The Ministry of Health recommends that two doses are given to individuals at high risk of meningococcal disease (see Table 13.5 and section 4.3), with booster doses every five years. If the first MenACWY-D dose was given before age 7 years, give a booster after three years then five-yearly.
A history of GBS is listed as a precaution in the MenACWY-D data sheet. However, there is no evidence of an association between meningococcal conjugate vaccines and GBS (see section 13.7.2). The Ministry of Health advises that, if indicated, MenACWY-D may be administered to individuals with a history of GBS.
The MenC data sheet states that the first dose of vaccine is not be given earlier than age 8 weeks. However, the Ministry of Health recommends that MenC may be given from age 6 weeks to infants at high risk of meningococcal disease (see Table 13.4 and Table 13.5).
The MenB data sheet states that the vaccine is indicated from age 2 months or older. However, the Ministry of Health recommends that MenB can be given from age 6 weeks to infants at high risk of meningococcal disease (see Table 13.5).The datasheet states that infants who received their primary course from ages 6 to 11 months can receive a booster in the second year of life at least 2 months later. The Ministry recommends that all infants aged 11 months or less receive a booster dose at least 6 months after the primary doses, from the age of 12 months.
The data sheet recommends two doses of MenB to be given eight weeks apart between ages 12 and 23 months and not less than one month apart from the age of 2 years. The Ministry of Health recommends two doses of MenB be given at least eight weeks apart for those aged 12 months or older at the time of the first dose.
- Campbell H, Parikh SR, Borrow R, et al. Presentation with gastrointestinal symptoms and high case fatality associated with group W meningococcal disease (MenW) in teenagers, England, July 2015 to January 2016. Euro Surveillance, 2016. 21(12).
- Ladhani SN, Beebeejaun K, Lucidarme J, et al. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clinical Infectious Diseases, 2015. 60(4): p. 578-85.
- Cohn A ,MacNeil J. The Changing Epidemiology of Meningococcal Disease. Infectious Disease Clinics of North America, 2015. 29(4): p. 667-77.
- Harrison LH, Granoff DM ,Pollard AJ. 2018. Meningococcal Capsular Group A, C, W and Y conjugate vaccines, in Plotkin's Vaccines (7th edition), Plotkin SA, Orenstein W, Offit P, et al. (eds). Elsevier: Philadelphia, US.
- Rubilar PS, Barra GN, Gabastou JM, et al. Increase of Neisseria meningitidis W:cc11 invasive disease in Chile has no correlation with carriage in adolescents. PloS One, 2018. 13(3): p. e0193572.
- Wang B, Santoreneos R, Giles L, et al. Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis. Vaccine, 2019. 37(21): p. 2768-2782.
- Meningococcal Disease Surveillance Group. Analysis of endemic meningococcal disease by serogroup and evaluation of chemoprophylaxis. Journal of Infectious Diseases, 1976. 134(2): p. 201-4.
- Neal KR, Nguyen-Van-Tam JS, Jeffrey N, et al. Changing carriage rate of Neisseria meningitidis among university students during the first week of term: cross sectional study. BMJ, 2000. 320(7238): p. 846-9.
- Bruce MG, Rosenstein NE, Capparella JM, et al. Risk factors for meningococcal disease in college students. JAMA, 2001. 286(6): p. 688-93.
- Nelson SJ, Charlett A, Orr HJ, et al. Risk factors for meningococcal disease in university halls of residence. Epidemiology and Infection, 2001. 126(2): p. 211-7.
- Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infectious Diseases, 2010. 10(12): p. 853-61.
- Peterson ME, Li Y, Shanks H, et al. Serogroup-specific meningococcal carriage by age group: a systematic review and meta-analysis. BMJ Open, 2019. 9(4): p. e024343.
- Baker M, McNicholas A, Garrett N, et al. Household crowding a major risk factor for epidemic meningococcal disease in Auckland children. Pediatric Infectious Disease Journal, 2000. 19(10): p. 983-90.
- Institute of Environmental Science and Research (ESR). 2022 Invasive meningococcal disease monthly report October 2022. Poirua, Wellington. URL: https://surv.esr.cri.nz/surveillance/Meningococcal_disease.php. (accessed 28 November 2022)
- Cohn AC, MacNeil JR, Harrison LH, et al. Effectiveness and Duration of Protection of One Dose of a Meningococcal Conjugate Vaccine. Pediatrics, 2017. 139(2).
- Villena R, Valenzuela MT, Bastias M, et al. Meningococcal invasive disease by serogroup W and use of ACWY conjugate vaccines as control strategy in Chile. Vaccine, 2019. 37(46): p. 6915-6921.
- Rennels M, King J, Jr., Ryall R, et al. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatric Infectious Disease Journal, 2004. 23(5): p. 429-35.
- Martinón-Torres F, Bertrand-Gerentes I ,Oster P. A novel vaccine to prevent meningococcal disease beyond the first year of life: an early review of MenACYW-TT. Expert Rev Vaccines, 2021. 20(9): p. 1123-1146.
- Chang LJ, Hedrick J, Christensen S, et al. A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States. Vaccine, 2020. 38(19): p. 3560-3569.
- Hedari CP, Khinkarly RW ,Dbaibo GS. Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease. Infect Drug Resist, 2014. 7(3 April): p. 85-99.
- Public Health England. 2016. Meningococcal. in The Green Book. URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/554011/Green_Book_Chapter_22.pdf. (accessed 3 July 2020)
- Cardoso CW, Ribeiro GS, Reis MG, et al. Effectiveness of meningococcal C conjugate vaccine in Salvador, Brazil: a case-control study. PloS One, 2015. 10(4): p. e0123734.
- Campbell H, Borrow R, Salisbury D, et al. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine, 2009. 27 Suppl 2(Suppl 2): p. B20-9.
- Maiden MC, Stuart JM ,U. K. Meningococcal Carraige Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet, 2002. 359(9320): p. 1829-31.
- Ramsay ME, Andrews NJ, Trotter CL, et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ, 2003. 326(7385): p. 365-6.
- Ladhani SN, Andrews N, Parikh SR, et al. Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England. New England Journal of Medicine, 2020. 382(4): p. 309-317.
- McMillan M, Wang B, Koehler AP, et al. Impact of Meningococcal B Vaccine on Invasive Meningococcal Disease in Adolescents. Clinical Infectious Diseases, 2021.
- McNamara LA, Thomas JD, MacNeil J, et al. Meningococcal Carriage Following a Vaccination Campaign With MenB-4C and MenB-FHbp in Response to a University Serogroup B Meningococcal Disease Outbreak-Oregon, 2015-2016. Journal of Infectious Diseases, 2017. 216(9): p. 1130-1140.
- Soeters HM, Whaley M, Alexander-Scott N, et al. Meningococcal carriage evaluation in response to a serogroup B meningococcal disease outbreak and mass vaccination campaign at a college – Rhode Island, 2015 – 2016. Clinical Infectious Diseases, 2017. 64(8): p. 1115-1122.
- Marshall HS, Lally N, Flood L, et al. First statewide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia. Medical Journal of Australia, 2020.
- Deceuninck G, Lefebvre B, Tsang R, et al. Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch. Vaccine, 2019. 37(31): p. 4243-4245.
- Ladhani SN, Campbell H, Andrews N, et al. First real world evidence of meningococcal group B vaccine, 4CMenB, protection against meningococcal group W disease; prospective enhanced national surveillance, England. Clinical Infectious Diseases, 2020.
- GlaxoSmithKline NZ Ltd, New Zealand Data sheet: Bexsero multicomponent meningococcal group B vaccine (recombinant, adsorbed). 2020, Medsafe.
- Martinón-Torres F, Bernatowska E, Shcherbina A, et al. Meningococcal B vaccine immunogenicity in children with defects in complement and splenic function. Pediatrics, 2018. 142(3).
- Arguedas A, Soley C, Loaiza C, et al. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine, 2010. 28(18): p. 3171-9.
- Gasparini R, Conversano M, Bona G, et al. Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults. Clinical and Vaccine Immunology, 2010. 17(4): p. 537-44.
- Rinderknecht S, Bryant K, Nolan T, et al. The safety profile of Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine (HibMenCY). Human Vaccines & Immunotherapeutics, 2012. 8(3): p. 304-11.
- Klein NP, Reisinger KS, Johnston W, et al. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants. Pediatric Infectious Disease Journal, 2012. 31(1): p. 64-71.
- Centers for Disease Control and Prevention. 2013. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report: Recommendations and Reports. 62(2): p. 1–28. https://www.cdc.gov/mmwr/pdf/rr/rr6202.pdf (accessed 27 February 2020)
- Pina LM, Bassily E, Machmer A, et al. Safety and immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants and toddlers: three multicenter phase III studies. Pediatric Infectious Disease Journal, 2012. 31(11): p. 1173-83.
- Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR: Recommendations and Reports, 2020. 69(9): p. 1-41.
- Drugs and Lactation Database (LactMed). 2006-. Meningococcal Vaccines. in Drugs and Lactation Database (LactMed). Bethesda MD. URL: https://www-ncbi-nlm-nih-gov.ezproxy.auckland.ac.nz/books/NBK501014/. (accessed 1 December 2022)
- American Academy of Pediatrics. 2018. Meningococcal disease. in Red Book: 2018 Report of the Committee on Infectious Diseases, Kimberlin D, Brady M, Jackson M, et al. (eds). Elk Grove Village, IL. p. 551-561. URL: https://redbook.solutions.aap.org/redbook.aspx. (accessed 15 April 2020)
- sanofi-aventis New Zealand. New Zealand datasheet: MenQuadfi. Medsafe; [updated 22 September 2022]; URL: https://www.medsafe.govt.nz/Profs/Datasheet/m/Menquadfiinj.pdf. (accessed 1 December 2022)
- Marshall GS, Pelton SI, Robertson CA, et al. Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age. Human Vaccines & Immunotherapeutics, 2022: p. 2099142.
- Velentgas P, Amato AA, Bohn RL, et al. Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination. Pharmacoepidemiology and Drug Safety, 2012. 21(12): p. 1350-8.
- Australian Technical Advisory Group on Immunisation. 2018. Australian Immunisation Handbook (ed.), Canberra: Australian Government Department of Health. URL: https://immunisationhandbook.health.gov.au/ (accessed October 2019)
- Conterno LO, Silva Filho CR, Ruggeberg JU, et al. Conjugate vaccines for preventing meningococcal C meningitis and septicaemia. Cochrane Database Syst Rev, 2006(3): p. CD001834.
- Vesikari T, Esposito S, Prymula R, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet, 2013. 381(9869): p. 825-35.
- Vesikari T, Prymula R, Merrall E, et al. Meningococcal serogroup B vaccine (4CMenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children. Vaccine, 2015. 33(32): p. 3850-8.
- Harcourt S, Morbey RA, Bates C, et al. Estimating primary care attendance rates for fever in infants after meningococcal B vaccination in England using national syndromic surveillance data. Vaccine, 2018. 36(4): p. 565-571.
- Zafack JG, Bureau A, Skowronski DM, et al. Adverse events following immunisation with four-component meningococcal serogroup B vaccine (4CMenB): interaction with co-administration of routine infant vaccines and risk of recurrence in European randomised controlled trials. BMJ Open, 2019. 9(5): p. e026953.
- Ministry of Health. 2012. Neisseria meningitidis invasive disease. in Communicable Disease Control Manual. Wellington. URL: https://www.health.govt.nz/publication/communicable-disease-control-manual. (accessed May 2022)
- Simmons G, Jones N ,Calder L. Equivalence of ceftriaxone and rifampicin in eliminating nasopharyngeal carriage of serogroup B Neisseria meningitidis. Journal of Antimicrobial Chemotherapy, 2000. 45(6): p. 909-11.
- Schaad UB, abdus Salam M, Aujard Y, et al. Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. Pediatric Infectious Disease Journal, 1995. 14(1): p. 1-9.